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Here we report on the development of a discriminatory real-time assay for the rapid identification of
Burkholderia pseudomallei isolates and the evaluation of this assay for sensitivity against related species and
detection in spiked human blood samples. The assay targets a 115-base-pair region within orf2 of the B.
pseudomallei type III secretion system gene cluster and distinguishes B. pseudomallei from other microbial
species. Assay performance was evaluated with 224 geographically, temporally, and clinically diverse B.
pseudomallei isolates from the Centers for Disease Control and Prevention strain collection. This represents the
first real-time PCR for rapid and sensitive identification of B. pseudomallei that has been tested for cross-
reactivity with 23 Burkholderia mallei, 5 Burkholderia thailandensis, and 35 Burkholderia and 76 non-Burkholderia
organisms which have historically presented diagnostic challenges. The assay performed with 100% specificity.
The limit of detection was found to be 76 femtograms of DNA (equivalent to 5.2  103 genome equivalents per
ml) in a single PCR. In spiked human blood, the assay could detect as few as 8.4  103 CFU per ml. This rapid
assay is a valuable tool for identification of B. pseudomallei and may improve diagnosis in regions endemic for
melioidosis.
Melioidosis, a disease caused by infection with Burkholderia
pseudomallei, is a significant public health burden in Southeast
Asia and northern Australia, where in some regions it is the
most common cause of fatal community-acquired bacteremic
pneumonia (6, 45). The ecological distribution of B. pseudoma-
llei is mostly limited to the tropical and subtropical areas be-
tween 20° north and south latitudes. While occasional cases of
melioidosis occur beyond these regions, outside the tropics
they have usually been associated with imported animals or
have occurred in travelers returning from these regions (6, 7,
12). Clinical manifestations of melioidosis range from asymp-
tomatic infection to focal infections in skin, muscle, bones,
joints, or internal organs to pneumonia, which can be chronic
or fulminant with rapidly fatal septicemia, where death can
occur within 48 h of symptom onset (6, 8, 45). B. pseudomallei
infection can resemble a number of other infections including
typhoid, tuberculosis, and malaria (45). High infectivity, sever-
ity of disease, and environmental persistence have resulted in
B. pseudomallei being classified as a category B select agent by
the Centers for Disease Control and Prevention (CDC) (31).
Culture remains the current “gold standard” for diagnosis of
melioidosis and identification of B. pseudomallei from a clinical
specimen (43, 48, 50). However, definitive identification relies
on a battery of traditional microbiological tests that can re-
quire up to a week to complete. Furthermore, some biochem-
ical identification methods for culture isolates are problematic,
especially rapid biochemical assays which have been shown to
misidentify B. pseudomallei as other bacteria such as Pseudo-
monas spp., Burkholderia vietnamiensis, Stenotrophomonas
maltophilia, and in particular Chromobacterium violaceum,
which can cause an infection with similar symptoms to melioid-
osis (14, 19, 23). Available serologic assays (dot immunoassay,
indirect hemagglutination assay, enzyme-linked immunosor-
bent assay, and immunochromatograpic test) are not particu-
larly useful in regions endemic for melioidosis because past
exposure to B. pseudomallei may result in seroconversion (6,
27, 45). Rapid bacterial detection from clinical samples using
latex agglutination or direct immunofluorescence has been suc-
cessful in Thailand, but these assays are not commercially
available (42, 49). Compounding the need for rapid diagnosis
is the lack of a human vaccine and the intrinsic resistance of B.
pseudomallei to many of the affordable antibiotic treatments
for general sepsis in areas endemic for the disease (7, 20, 45).
In addition to accelerating appropriate therapeutic interven-
tion, improved rapid diagnostic tests could potentially prevent
unnecessary laboratory-acquired infection due to overhandling
of clinical specimens containing B. pseudomallei and would
facilitate surveillance prior to and following deliberate release
(3, 5, 7, 31).
The complete sequence of the B. pseudomallei genome re-
veals several gene targets for the identification of this species
(e.g., 16S rRNA genes, fliC, rpsU, and type III secretion [TTS]
gene cluster) (18, 25, 26, 36, 38, 39). This approach to PCR
target identification and primer and probe design and im-
proved methods for fluorescence labeling of DNA allow for the
in silico design and evaluation of real-time PCR assays specific
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for a given species (15, 24, 29, 30). The disadvantage of a
purely theoretical approach is choosing gene targets based on
one strain, which may not be representative of the global B.
pseudomallei population, resulting in false-negative results.
Thus for this study we chose a target based on not only its
theoretical specificity but also its apparent ubiquitous popula-
tion distribution (35). Previously, a 548-bp region of the B.
pseudomallei type III secretion system (TTS1) gene cluster
encompassing part of open reading frame 2 (orf2) was found to
be present in B. pseudomallei and not in the related Burkhold-
eria mallei or Burkholderia thailandensis (28, 46, 47). This open
reading frame was later found to be present in all of a large
number of northern Australian B. pseudomallei strains (35).
We report here the design and evaluation of a fluorescence-
labeled-probe-based real-time PCR assay targeting orf2 of the
TTS1 of B. pseudomallei (TTS1 real-time PCR). The sensitiv-
ity, specificity, low limit of detection, and lack of interaction
with human DNA make this assay a good candidate for diag-
nostic clinical laboratory evaluation.
MATERIALS AND METHODS
Collection and preparation of bacterial strains. Bacterial strains were ob-
tained from CDC culture collections housed in the Meningitis and Special
Pathogens Branch. They included 224 B. pseudomallei strains representing tem-
poral (1949 to 2004), geographic (Americas, Asia, Europe, Africa, and Oceania),
and origin diversity (human, environmental, animal). The geographic regions
covered by this collection represent the locale of isolation and not necessary
where infection occurred. Isolates from regions not traditionally considered
endemic for melioidosis such as North America and Europe represent imported
cases. In addition, 23 B. mallei strains, 5 B. thailandensis strains, and 111 non-B.
pseudomallei strains were evaluated for cross-reactivity (Table 1). All strains
were stored at 70°C in defibrinated rabbit blood until they were tested. Iden-
tification of strains was carried out with a standard battery of biochemical tests
(44). Culture isolates were not available from six of the diagnostically challenging
organisms (Mycobacterium tuberculosis, Francisella tularensis, Plasmodium falci-
parum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae). For
these pathogens DNA was obtained from subject matter expert laboratories and
tested directly.
DNA preparation. Isolates were cultured on standard media at 37°C overnight.
For testing assay specificity whole-cell DNA extractions were prepared from the
cultures by heat lysis as previously described by Hoffmaster et al. (17). The assay
sensitivity was evaluated using purified B. pseudomallei genomic DNA extracted
TABLE 1. Microorganisms (n  139) used to test the specificity of the TTS1 real-time PCR assay
Isolate category Species, genomovar, serovar, serogroup, and/or straina No. tested
Genetic relatives (n  78) Burkholderia cepacia genomovar I/III, B. multivorans, B. stabilis, B. gladioli,
B. vietnamiensisT, B. cocovenenans, Burkholderia sp. strain Oklahoma
35
Burkholderia mallei 23
Burkholderia thailandensis 5
Pandoraea apista, P. norimbergensis, P. pnomenusaT, P. sputorum 8
Ralstonia paucula, R. pickettii Ralstonia sp. 7
Differential diagnoses (n  11) Acinetobacter baumanniiT 1
Mycobacterium tuberculosisT 1
Plasmodium falciparumT, P. malariaeT, P. ovaleT, P. vivaxT 4
Staphylococcus aureus 1
Vibrio cholerae 2
Yersinia enterocolitica O:9, Y. enterocolitica 2
Potential misidentifications (n  6) Alcaligenes faecalis 1
Chromobacterium violaceum 3
Stenotrophomonas maltophilia 2
Select agents (n  6) Bacillus anthracis 2
Brucella abortus, B. melitensis, B. suis 3
Francisella tularensis subsp. holarctica strain LVS 1
Potential sample contaminants (n  38) Achromobacter xylosoxidans 1
Aeromonas hydrophilaT 1
Afipia broomeae 1
Bartonella clarridgeiaeT, B. henselaeT 2
Bacillus cereus 3
Brucella canis 1
Candida albicansT 1
Enterobacter aerogenes 1
Escherichia coli serotype O157:H7, E. coliT 2
Haemophilus influenzae 2
Klebsiella pneumoniae 1
Legionella pneumophilaT 1
Ochrobactrum anthropi 5D 3
Proteus mirabilisT, P. vulgaris 2
Pseudomonas aeruginosaT, P. mendocina, P. putida, P. stutzeri 9
Psychrobacter phenylpyruvicusT 1
Rothia dentocariosa 1
Salmonella enterica serovar Urbana, Salmonella spp. 3
Sphingobacterium multivorum 1
Streptococcus pneumoniae 1
a Superscript T indicates the type strain.
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with the DNeasy tissue kit (QIAGEN, Valencia, CA) using the manufacturer’s
instructions for gram-negative bacteria. For spiked human blood samples, DNA
was isolated from a 200-l sample using a modified protocol for the QIAmp
DNA blood kit (QIAGEN), substituting proteinase K for protease and buffer
ATL for AL and using an elution volume of 200 l. The procedure was modified
to add a 10-min 70°C step to ensure lysis of bacterial cells. The DNA concen-
trations were determined using a spectrophotometer (NanoDrop Technologies,
Wilmington, DE), and the numbers of genome equivalents (GE) were calculated
using the 7.25-Mbp genome (68% GC) of B. pseudomallei K96243 (18).
Real-time PCR assay. Primer pair and probe were designed to target the type
III secretion system gene cluster of B. pseudomallei (GenBank accession no.
AF074878) using Primer Express 2.0 (Applied Biosystems, Inc., Foster City, CA),
BpTT4176F (5-CGTCTCTATACTGTCGAGCAATCG-3), and BpTT4290R
(5-CGTGCACACCGGTCAGTATC-3). The primer pair was designed to gen-
erate a 115-bp PCR product. The fluorogenic probe BpTT4208P (5-CCGGAA
TCTGGATCACCACCACTTTCC-3) was synthesized with a 6-carboxyfluores-
cein reporter molecule attached at the 5 end and a Black Hole Quencher 1 on
the 3 end. The primers and probe were synthesized in the Biotechnology Core
Facility at the CDC.
Each TTS1 real-time PCR mixture contained a 2-l aliquot of extracted DNA
in 23 l of a PCR master mixture containing 1 LightCycler Faststart DNA
master hybridization probe reaction mixture (Roche Applied Sciences, India-
napolis, IN), 5 mM MgCl2, 400 nM of each primer, and 200 nM of probe.
Amplification and detection were performed with a SmartCycler (Cepheid,
Sunnyvale, CA) using the standard settings. The SmartCycler thermal cycling
conditions were 95°C for 8 min, followed by 45 cycles of 15 s at 95°C and 15 s at
59°C. The cycle threshold values represent the calculated cycles at which fluo-
rescence from the cleaved probe exceeds a fixed threshold, as calculated by the
instrument for each reaction. No-template (PCR grade water) and positive (B.
pseudomallei CDC2000032028) controls were included in each run to rule out the
possibility of contamination or amplification failure. The sensitivity and speci-
ficity of the real-time PCR assay were evaluated by testing 1 ng of extracted
DNA.
The lower limit of detection (LLOD), linear dynamic range (LDR), and assay
variance for the TTS1 real-time PCR were determined using purified B.
pseudomallei (CDC2000032028) DNA (13). For LDR and variance analysis, five
replicates from a 10-fold serial dilution (108 to 103 GE/ml) of purified DNA in
elution buffer (QIAGEN, Valencia, CA) were assayed in a single run. To deter-
mine LLOD, an additional five replicates from a 10-fold serial dilution (102 to
102 GE/ml) of purified DNA were added. Eight separate replicate experiments
were conducted using aliquots of DNA frozen at 20°C. These data were
compared to those obtained from DNA extractions of six spiked human blood
samples (Lampire Biological, Coopersburg, PA, and CDC Blood Services
Group, Atlanta, GA). Previous studies have highlighted the need for preassay
enrichment of clinical samples to achieve DNA concentrations in the range of
real-time detection (38, 39). Therefore, we designed an evaluation of the assay
for detecting B. pseudomallei cells in human blood. An aliquot of the uninocu-
lated whole human blood (with EDTA as a non-PCR-inhibiting anticoagulant)
was plated prior to each experiment to check for sterility. Colonies from over-
night cultures of B. pseudomallei (CDC2000032028) were suspended in phos-
phate-buffered saline (PBS) at a concentration equivalent to 109 cells per ml
based on McFarland turbidimetric standards. Serial 10-fold dilutions (108 to
102 CFU/ml) were made from the solution in blood and PBS. Aliquots from
each series of dilutions were used for spread plates in triplicate, and the average
CFU/ml was calculated. Four replicates of each series were assayed.
Data and statistical analysis. The LLODs were determined using a model of
nonlinear regression (PriProbit version 1.63). The LDR and the coefficient-of-
variation calculations for the assay were carried out with Excel (Microsoft). The
PCR efficiency (E) of the primer pair and probe was calculated using the equa-
tion E  101/slope  1 (40). An E of 1.0 indicates that amplicon quantity is
duplicated every cycle.
RESULTS
Sensitivity and specificity. The assay successfully amplified
DNA from all 224 B. pseudomallei strains in the CDC culture
collection. The cycle threshold values ranged from 19 to 27 for
the whole-cell extracts. Using a nonlinear-regression model,
the LLOD from purified B. pseudomallei (CDC2000032028)
DNA was 76 fg/PCR (equivalent to 5.2  103 GE/ml) (Fig.
1A), and the LDR was 3.3  104 GE/ml to 3.3  108 GE/ml
(Fig. 1B). Intra-assay variance was estimated in the LDR to be
between 0.39 and 1.64%, while the interassay variability was
between 1.00 and 1.76%.
The specificity of the designed primers and probe was as-
sessed first in silico by comparing the sequences and the gene
product using BLAST (2). There were no sequences in the
database producing alignments with significant expectation values
or sharing regions of significant similarity to the primers or probe.
All non-B. pseudomallei isolates were negative (Table 1).
These included genetic relatives (e.g., Burkholderia mallei, B.
thailandensis, and Ralstonia spp.), biothreat agents (e.g., Bacil-
lus anthracis, Brucella spp., and Francisella tularensis), and
pathogens that are part of the differential diagnoses for me-
lioidosis (e.g., Staphylococcus aureus, Plasmodium spp., Salmo-
nella spp., and Mycobacterium tuberculosis). Organisms that
cause frequent misidentifications using rapid biochemical as-
says (e.g., Pseudomonas spp., Burkholderia vietnamiensis, Burk-
holderia cepacia, Stenotrophomonas maltophilia, and Chro-
mobacterium violaceum) were negative by the TTS1 real-time
assay.
Assay of spiked blood samples. Human DNA was nonreac-
tive by the TTS1 real-time PCR. Five separate experiments
were performed using spiked blood samples from five different
donors with heterogeneous blood types and travel histories.
FIG. 1. Limits of detection and linear dynamic range of TTS1 PCR
using Burkholderia pseudomallei DNA extracts. (A) Probit nonlinear
regression analysis of the real-time PCR assay’s detection of the TTS1
gene target. (B) Dynamic range analysis of the real-time PCR assay’s
detection of the TTS1 gene target. The regression line represents data
in the linear range. Error bars equal two standard deviations of the
aggregate mean. The slope, correlation coefficient (R2), and PCR ef-
ficiency (E) are displayed.
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Mean assay results were used to establish an LLOD of 8.4 
103 CFU/ml (Fig. 2A) and the LDR of 5.4  104 to 5.4  108
CFU/ml (Fig. 2B). The regression coefficient (R2  0.99) and
the amplification efficiency value (E  1.17) demonstrated an
exponential amplification of DNA with this probe and primer
pair.
DISCUSSION
Melioidosis is a significant public health burden in regions of
Southeast Asia and northern Australia. Septicemic melioid-
osis, if left untreated, is a rapidly progressing infection that has
a mortality rate as high as 90% (45). In regions not endemic for
melioidosis Burkholderia pseudomallei is also of concern be-
cause of its potential release during a biothreat event. There-
fore, we developed a real-time PCR for rapid identification of
B. pseudomallei isolates that potentially offers a faster and
more reliable diagnosis of disease in regions endemic for me-
lioidosis. Rapid identification of B. pseudomallei is especially
important in these regions because of the high prevalence of B.
pseudomallei strains that are resistant to the antibiotics typi-
cally used to empirically treat sepsis (20, 45). Other methods of
rapid identification such as latex agglutination are not com-
mercially available. Here we have described the development
and evaluation of a rapid, sensitive real-time assay for the
specific identification of B. pseudomallei. The real-time assay
targeting orf2 of the B. pseudomallei type III secretion system
accurately distinguished a large sample of diverse B.
pseudomallei isolates from non-B. pseudomallei isolates (100%
specificity) and was not inhibited by human blood products or
DNA.
A number of rapid presumptive biochemical and PCR assays
have been developed and evaluated for the identification of B.
pseudomallei (14, 16, 21, 27, 32, 51). The molecular methods
for identification of B. pseudomallei infection include a number
of conventional PCRs with various specificities that also may
suffer from a lack of sensitivity (16, 22, 32, 51). More recently
two real-time PCR assays have been developed and well eval-
uated on bacterial isolates (36, 38, 39). Both real-time assays
had greater sensitivity than the traditional PCR assays and
appear specific for the identification of isolates of B.
pseudomallei or the B. pseudomallei/B. mallei complex. This
increased sensitivity suggests that they may be suitable for
clinical samples, but both assays may require DNA or cell
preassay enrichment to detect bacteremic infections. There
have been no reported evaluations of either assay for diagnosis
of melioidosis in a clinical setting.
Estimates of the concentration of B. pseudomallei in blood
for septicemic melioidosis patients range from 1 to 1,000 CFU
per ml (33, 37, 41). The onset of melioidosis symptoms for a
given blood cell count varies depending on a combination of
isolate virulence and host factors (9, 10, 35). Based on exper-
iments with B. pseudomallei-spiked blood the TTS1 real-time
assay has a 95% probability of detecting a concentration of 8.4
 103 CFU/ml with a single PCR (Fig. 2A). Following analysis
of DNA extracted from multiple dilutions of B. pseudomallei-
spiked human blood samples, the lowest concentration that
yielded at least one positive target amplification was 500 CFU/
ml, equaling a 12.5% probability of detection (Fig. 2A). By
increasing the assay volume of extracted clinical DNA in this
system fivefold and testing multiple replicates, the probability
of detecting a positive clinical sample using the TTS1 real-time
assay is likely to improve. Assuming a Poisson distribution of
sample DNA, a clinical specimen with 500 cells/ml has an
extrapolated probability of detection of 100% in at least two of
three replicate samples with this fivefold increase in sample
volume.
These results suggest that early bacteremia may be beyond
the limit of detection of the current assay conditions. Data
presented here were based on DNA extracted from spiked
blood samples; no attempt to concentrate the cells or DNA
was made prior to extraction. Early detection may be accom-
plished by assaying a concentrated sample either through pre-
processing of a blood specimen or collecting a clinical speci-
men with a higher cell concentration such as sputum or wound
exudate from a focal infection site (B. Currie, personal com-
munication). An adjusted assay reduces the time for presump-
tive diagnosis from days to 3 h, allowing for early definitive
antibiotic intervention and minimizing laboratorian contact
time.
The power of a well-designed and evaluated real-time PCR
assay is demonstrated by its ability to detect target DNA in the
FIG. 2. Limits of detection and linear dynamic range of TTS1 PCR
using Burkholderia pseudomallei-spiked human blood. (A) Probit non-
linear regression analysis of the real-time PCR assay’s detection of the
TTS1 gene target. (B) Dynamic range analysis of the real-time PCR
assay’s detection of the TTS1 gene target. The regression line repre-
sents data in the linear range. Error bars equal two standard deviations
of the aggregate mean. The slope, correlation coefficient (R2), and
PCR efficiency (E) are displayed.
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presence of a vast excess of other nontarget DNA (24). During
outbreaks of melioidosis associated with severe weather events
such as cyclones, after natural disasters such as tsunamis, or
following a bioterror release, large numbers of patients could
potentially overwhelm the capacity of a health care facility (1,
10). A reliable single target assay could rapidly screen large
numbers of patients using multiple specimens from usually
sterile (blood or urine), and nonsterile (wound, throat, or spu-
tum) clinical sites to identify those needing immediate antibi-
otic therapy for melioidosis (34).
Testing environmental samples containing diverse microbial
ecology may be enhanced by the use of a selective identifica-
tion technique such as the TTS1 real-time PCR, but this re-
quires further evaluation. Also, large-scale environmental sur-
veys to establish ecological distribution and concentration
using this assay would be a benefit in endemic areas for me-
lioidosis.
The real-time PCR assay targeting orf2 of the B. pseudoma-
llei type III secretion system is a powerful tool for the rapid
identification of B. pseudomallei and can potentially comple-
ment current confirmatory diagnostic procedures for melioid-
osis. Further studies to evaluate the TTS1 real-time assay on a
larger panel of environmental samples, including an evaluation
of more B. thailandensis strains, are needed. This less-virulent
close relative of B. pseudomallei is a common soil saprophyte in
the hyperendemic melioidosis region of northeast Thailand (4,
11). The evaluation of rapid diagnostic assays using clinical
samples in a region of melioidosis endemicity is necessary for
an accurate assessment of the clinical efficacy of proposed new
diagnostic tools and is under way as part of an ongoing pro-
spective melioidosis cohort study in northern Australia.
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